Niacin ER

DRUG2 trials

Sponsors

University of Pennsylvania, Karyopharm Therapeutics Inc

Conditions

Metabolic SyndromeNHLSolid Tumors

Phase 1

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

TerminatedNCT02702492

Karyopharm Therapeutics IncNHL, Solid Tumors

Start: 2016-06-08End: 2021-01-26Updated: 2024-11-25

Phase 2

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

CompletedNCT00300365

University of PennsylvaniaMetabolic Syndrome

Start: 2005-11-30End: 2010-08-31Updated: 2017-07-28

Related Papers

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

Targeted Oncology2026-03-13

Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma

Blood2021-11-05

Abstract 4368: PAK4-NAMPT dual inhibition as a feasible strategy for treatment of resistant pancreatic neuroendocrine tumors

Cancer Research2018-07-01

EXTH-84. TARGETING THE SALVAGE PATHWAY OF NAD+ GENERATION IN GLIOMAS BY KPT-9274, A NOVEL DUAL INHIBITOR OF PAK4 AND NAMPT

Neuro-Oncology2017-11-01

Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma

Cancer Research2017-07-015 citations

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics2016-11-1687 citations